Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.
Frequently asked questions
What sector does Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) operate in?
Gwo Xi Stem Cell Applied Technology Co. , Ltd belongs to the Other sector and operates in the Biotechnology industry.
What is Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) current stock price?
As of the latest data, Gwo Xi Stem Cell Applied Technology Co. , Ltd stock price is NT$19.00, with a previous close of NT$19.00.
What is Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) current market capitalization?
Gwo Xi Stem Cell Applied Technology Co. , Ltd market cap is approximately 1.82 billion.
What is Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.84.
Does Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) pay dividends?
No. Gwo Xi Stem Cell Applied Technology Co. , Ltd does not pay a dividend.
What is Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) beta (volatility) score?
Gwo Xi Stem Cell Applied Technology Co. , Ltd has a beta of 0.069, indicating lower volatility than the overall market.
